Myositis

Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer .Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs
Rohit Aggarwal ( View Tweet )
Nov 16, 2023
#ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis -Anti-NT5c1A assoc with dysphagia -Anti-Ro52/TRIM21: female -Anti-VCP: male -Anti-NT5c1A + clinical markers: high accuracy in separating SIBM vs AIM Need longitudinal data for clusters to be meaningful @RheumNow https://t.co/fu0a074XAZ
Md Yuzaiful Md Yusof ( View Tweet )
Nov 15, 2023
#ACR23 Abstr#2580 Could high-intensity resistance training improve outcomes in myositis? RCT showed 16 wks of training was tolerable, improved quality of life & functional capacity, without increasing disease activity/damage @RheumNow https://t.co/O1nP2x9C1L
Md Yuzaiful Md Yusof ( View Tweet )
Nov 15, 2023
Don’t forget: 👉anti-HMGCR Ab in patients with immune mediated necrotizing myositis (may be assc with statins) 👉Anti-synthetase Ab assc with ILD, anti-synthetase syndrome #Rheum #BoardQuestion https://t.co/pBAADeR9ON

TheDaoIndex @KDAO2011( View Tweet )

Nov 14, 2023
RheumNow Podcast square

Sleep Apnea Smart Watches (10.13.2023)

Jack Cush, MD
Oct 13, 2023

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.




  1. Full Read review of #PMR in Lancet: - Start @ 12·5–25mg prednisone qd - Remission in most but, relapses in 40–60% - Onset sudden; AM stiffness predominates;

Read Article
RheumNow Podcast square

Hard Decisions in RA (9.1.2023)

Jack Cush, MD
Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
RheumNow Podcast square

Mono- and Oligo- are Different (8.18.2023)

Jack Cush, MD
Aug 18, 2023

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.




  1. Glucocorticoid Affects Weight, but not Blood Pressure in RA A pooled analysis of 5 RCTs shows that the effects of 2 years of low-dose glucocorticoid (GC) treatment in RA can significantly

Read Article
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

Jack Cush, MD
Aug 11, 2023

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:




  1. Swedish study of 325 #AAV pts saw CVA in 35 pts (8%); CVA incidence=11.3/1000 PYs - this was higher than gen population [SIR 1.85). AAV CVA risk factors included age

Read Article
RheumNow Podcast square

English for the Biologically-Challenged (8.4.2023)

Jack Cush, MD
Aug 04, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include: - rapidly progressive interstitial lung disease - anti-Ro52 antibody - age > 57 years (based on study of 126 MDA-5+ DM pts) https://t.co/VCyLhStFgX https://t.co/y3CyzOlwDt

Links:

Dr. John Cush @RheumNow( View Tweet )
Aug 02, 2023
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/VKsxT34lga https://t.co/VGaFmsYUrP

Links:

Dr. John Cush @RheumNow( View Tweet )
Jul 26, 2023
NEJM: 19 yoM w/ 3yr hx of Raynauds, periungual erythema. Nailfold capillaroscopy showed giant nailfold capillaries, branched & bushy neovascularized capillary loops & reduced capillary density; suggesting clinically amyopathic dermatomyositis https://t.co/Wvnp7wCajx

Links:

Dr. John Cush @RheumNow( View Tweet )

Jul 25, 2023
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush @RheumNow( View Tweet )

Jul 03, 2023
Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/0B1zzeqm1L

Links:

Dr. John Cush @RheumNow( View Tweet )

Jul 03, 2023
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/3xL0ylJbcs https://t.co/Oerf0yI4Jg

Links:

Dr. John Cush @RheumNow( View Tweet )
Jul 01, 2023
RheumNow Podcast square

Scleroderma – Thick and Thin (6.30.2023)

Jack Cush, MD
Jun 30, 2023

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.

Read Article
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/CG9ClLHEW6 https://t.co/DPekHWjTsP

Links:

Dr. John Cush @RheumNow( View Tweet )
Jun 27, 2023
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta @bella_mehta( View Tweet )
Jun 03, 2023
#EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few years @RheumNow https://t.co/Oh8sZlMzUt
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 02, 2023
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush @RheumNow( View Tweet )

Jun 01, 2023
Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0
Dr. John Cush @RheumNow( View Tweet )
Jun 01, 2023
Professor Ingrid Lundberg reviews the co associations amongst the inflammatory myopathies #EULAR2023 https://t.co/B9Idyz90Lh
Dr. John Cush @RheumNow( View Tweet )
Jun 01, 2023
Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG). https://t.co/tYOwsNaiGy https://t.co/Bpfft4J9MB

Links:

Dr. John Cush @RheumNow( View Tweet )
May 15, 2023
Clot.DVT_.VTE_.blood_.jpg

Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis

Jack Cush, MD
May 11, 2023

A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).



Previous studies have shown an increased risk of VTE in DM patients, usually within 2 years of onset. Moreover, the FDA has recently

Read Article
RheumNow Podcast square

The Match Game (4.14.2023)

Jack Cush, MD
Apr 14, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.




  1. 2023 NRMP Match: 365 applicants for Rheum; 97.8% (265 of 271

Read Article

Recent Blogs

A Winning Season*

Jack Cush, MD
Sep 09, 2015
football.jpg

Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.

Read Post

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×